Curevac AG

U.S. Patent No. 11,135,312

$2,500.00

This prior art search report presents the mappings of the various elements of claim 1 of U.S. Patent No. 11,135,312 (‘312 Patent), titled “Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions”, from assignee Curevac AG, published on 5 October 2021.

The patent discloses a method of synthesizing a stabilized mRNA molecule where the stabilized mRNA molecule comprises a coding sequence with an increased Guanine/Cytosine (G/C) content relative to the original coding sequence. The G/C content has an increase of at least 7 percentage points and the increase resulted in the elimination of at least one destabilizing sequence element. The stabilized mRNA also exhibits an enhanced expression of the polypeptide.

This preliminary search report includes the following:

References found from the preliminary search
Claims mapping chart
Copies of the selected references with highlighted excerpts
Search strategies used in conducting the prior art search

Add to Cart

Disclaimer

This ParolaPRIME™ report is not legal advice. The suggested correspondences between the features disclosed in the patent-at-issue and those disclosed in each reference reflect what Parola Analytics believes are technical similarities between those respective sets of features. Parola Analytics makes no representation concerning any legal status or effect that may arise from documents mentioned in this report, such as the validity of any apparent priority date or the assertability of any document as prior art against a patent. You should independently obtain legal counsel before attempting to rely on any portion of this report in a legal proceeding.

The references presented in this report are only preliminary and do not represent results from an exhaustive search. For the full report, request a quote.

Questions? Read our Terms and Conditions, FAQs or contact us.